X4 Pharmaceuticals, Inc (XFOR) stock
XFORNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$3.09+0.26 (+9.19%)
Close on Nov 17, 2026Market cap $306.36MP/E –Yield –
X4 Pharmaceuticals cash
Cash and short-term investments held at the end of each period.
X4 Pharmaceuticals's cash was $187.70M at Sep 30, 2026. For fiscal 2025 it was $253.00M, up 147.8% from the year before. Over ten years it grew 43.0% a year on average. The highest annual figure on record is $253.00M in fiscal 2025.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $253.00M | +147.8% |
| FY2024 | Dec 31, 2024 | $102.10M | -10.6% |
| FY2023 | Dec 31, 2023 | $114.20M | -7.2% |
| FY2022 | Dec 31, 2022 | $123.03M | +48.0% |
| FY2021 | Dec 31, 2021 | $83.11M | +3.0% |
| FY2020 | Dec 31, 2020 | $80.70M | -37.0% |
| FY2019 | Dec 31, 2019 | $128.09M | +1474.7% |
| FY2018 | Dec 31, 2018 | $8.13M | -69.5% |
| FY2017 | Dec 31, 2017 | $26.68M | +76.0% |
| FY2016 | Dec 31, 2016 | $15.16M | +113.6% |
| FY2015 | Dec 31, 2015 | $7.10M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $187.70M | +53.6% |
| Q2 FY2026 | Jun 30, 2026 | $208.00M | +230.2% |
| Q1 FY2026 | Mar 31, 2026 | $233.70M | +168.6% |
| Q4 FY2025 | Dec 31, 2025 | $253.00M | +147.8% |
| Q3 FY2025 | Sep 30, 2025 | $122.20M | -9.5% |
| Q2 FY2025 | Jun 30, 2025 | $63.00M | -62.7% |
| Q1 FY2025 | Mar 31, 2025 | $87.00M | +7.5% |
| Q4 FY2024 | Dec 31, 2024 | $102.10M | -10.6% |
| Q3 FY2024 | Sep 30, 2024 | $135.00M | -4.5% |
| Q2 FY2024 | Jun 30, 2024 | $168.80M | +78.8% |
| Q1 FY2024 | Mar 31, 2024 | $80.90M | -34.2% |
| Q4 FY2023 | Dec 31, 2023 | $114.20M | +40.7% |
| Q2 FY2023 | Jun 30, 2023 | $141.30M | +190.2% |
| Q1 FY2023 | Mar 31, 2023 | $94.43M | +39.4% |
| Q4 FY2022 | Dec 31, 2022 | $123.03M | +48.0% |
| Q3 FY2022 | Sep 30, 2022 | $81.15M | +4.4% |
| Q2 FY2022 | Jun 30, 2022 | $48.68M | -49.5% |
| Q1 FY2022 | Mar 31, 2022 | $67.74M | -41.9% |
| Q4 FY2021 | Dec 31, 2021 | $83.11M | +3.0% |
| Q3 FY2021 | Sep 30, 2021 | $77.72M | -12.5% |
| Q2 FY2021 | Jun 30, 2021 | $96.49M | -7.0% |
| Q1 FY2021 | Mar 31, 2021 | $116.66M | +1.4% |
| Q4 FY2020 | Dec 31, 2020 | $80.70M | -37.0% |
| Q3 FY2020 | Sep 30, 2020 | $88.81M | +16.5% |
| Q2 FY2020 | Jun 30, 2020 | $103.74M | +15.0% |
| Q1 FY2020 | Mar 31, 2020 | $115.05M | +416.0% |
| Q4 FY2019 | Dec 31, 2019 | $128.09M | +1474.7% |
| Q3 FY2019 | Sep 30, 2019 | $76.25M | +674.9% |
| Q2 FY2019 | Jun 30, 2019 | $90.18M | +617.7% |
| Q1 FY2019 | Mar 31, 2019 | $22.30M | +16.1% |
| Q4 FY2018 | Dec 31, 2018 | $8.13M | -69.5% |
| Q3 FY2018 | Sep 30, 2018 | $9.84M | -62.5% |
| Q2 FY2018 | Jun 30, 2018 | $12.57M | -48.0% |
| Q1 FY2018 | Mar 31, 2018 | $19.21M | +741.6% |
| Q4 FY2017 | Dec 31, 2017 | $26.68M | +76.0% |
| Q3 FY2017 | Sep 30, 2017 | $26.25M | +269.9% |
| Q2 FY2017 | Jun 30, 2017 | $24.14M | – |
| Q1 FY2017 | Mar 31, 2017 | $2.28M | – |
| Q4 FY2016 | Dec 31, 2016 | $15.16M | – |
| Q4 FY2015 | Dec 31, 2015 | $7.10M | – |
See a number that looks wrong?